Anti-inflammatory action of a hyaluronic acid-chondroitin sulfate preparation in an in vitro bladder model;Antientzündliche Wirkung Einer Hyaluronsäure-Chondroitinsulfat- Präparation im In-vitro-Blasenmodell

Aktuelle Urologie

Volumn 40, Issue 2, 2009, Pages 109-112

  Schulz, A ^a   Vestweber, A M ^b   Dressler, D ^a  

^a BIOTESYS GMBH   (Germany)

^b Farco Pharma GmbH   (Germany)

Author keywords

Cystitis; Human cell line; Interstitial; Intravesical instillation; Model; Urinary bladder

Indexed keywords

CHONDROITIN SULFATE; HYALURONIC ACID; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 5; LIPOPOLYSACCHARIDE; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL LINE; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECT; ESCHERICHIA COLI; FEASIBILITY STUDY; HUMAN; IMMUNOLOGY; IN VITRO STUDY; INTERSTITIAL CYSTITIS; METABOLISM; UROTHELIUM;

ADJUVANTS, IMMUNOLOGIC; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELL LINE; CELL SURVIVAL; CHONDROITIN SULFATES; CYSTITIS, INTERSTITIAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ESCHERICHIA COLI; FEASIBILITY STUDIES; HUMANS; HYALURONIC ACID; INTERLEUKIN-5; LIPOPOLYSACCHARIDES; TUMOR NECROSIS FACTOR-ALPHA; UROTHELIUM;

EID: 63849246507     PISSN: 00017868     EISSN: 14388820     Source Type: Journal    
DOI: 10.1055/s-0028-1098784     Document Type: Article

References (14)

1. van de Merwe JP, Nordling J, Bouchelouche P et al. Diagnostic criteria, Classification, and nomenclature for painful bladder syndrome/interstitial cystitis: an ESSIC proposal. Eur Urol 2008; 53: 60-67
2. van Ophoven A, Oberpenning F. [Interstitial cystitis. An important differential diagnosis]. Urologe A 2006; 45: 451-456
3. Hurst RE, Roy JB, Min KW et al. A deficit of chondroitin sulfate proteoglycans on the bladder uroepithelium in interstitial cystitis. Urology 1996; 48: 817-821
4. van Ophoven A. Therapie der interstitiellen Zystitis mittel Blaseninstillation. Journal für Urologie und Urogynäkologie 2007; 14: 29-31
5. Parsons M, Toozs-Hobson P. The investigation and management of interstitial cystitis. J Br Menopause Soc 2005; 11: 132-139
6. Kyker KD, Coffman J, Hurst RE. Exogenous glycosaminoglycans coat damaged bladder surfaces in experimentally damaged mouse bladder, BMC Urol 2005; 5: 4
7. Toft BR, Nordling J. Recent developments of intravesical therapy of painful bladder syndrome/interstitial cystitis: a review. Curr Opin Urol 2006; 16: 268-272
8. Okamoto M, Hattori K, Oyasu R. Interleukin-6 functions as an autocrine growth factor in human bladder carcinoma cell lines in vitro. Int J Cancer 1997; 72: 149-154
9. Julovi SM, Yasuda T, Shimizu M et al. Inhibition of interleukin-1 beta-stimulated production of matrix metalloproteinases by hyaluronan via CD44 in human articular cartilage. Arthritis Rheum 2004; 50: 516-525
10. Hiramitsu T, Yasuda T, Ito H et al. Intercellular adhesion molecule-1 mediates the inhibitory effects of hyaluronan on interleukin-1 beta-induced matrix metalloproteinase production in rheumatoid synovial fibroblasts via down-regulation of NF-kappaB and p38. Rheumatology (Oxford) 2006; 45: 824-832
11. Yasuda T. Hyaluronan inhibits cytokine production by lipopolysaccharide-stimulated U937 macrophages through down-regulation of NF-kappaB via ICAM-1. Inflamm Res 2007; 56: 246-253
12. Muthukumaran N, Miletti-Gonzalez KE, Ravindranath AK et al. Tumor necrosis factor-alpha differentially modulates CD44 expression in ovarian cancer cells. Mol Cancer Res 2006; 4: 511-520
13. Wang CT, Lin YT, Chiang BL et al. High molecular weight hyaluronic acid down-regulates the gene expression of osteoarthritis-associated cytokines and enzymes in fibroblast-like synoviocytes from patients with early osteoarthritis. Osteoarthritis Cartilage 2006; 14: 1237-1247
14. Campo GM, Avenoso A, Campo S et al. Purified human plasma glycosaminoglycans reduced NF-{kappa}B activation, pro-inflammatory cytokine production and apoptosis in LPS-treated chondrocytes. Innate Immun 2008; 14: 233-246